Targeted nuclear imaging of breast cancer: Status of radiotracer development and clinical applications

Cancer Biotherapy and Radiopharmaceuticals

Volumn 27, Issue 2, 2012, Pages 105-112

  Kong, Fan Lin ^a   Kim, E Edmund ^a   Yang, David J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

breast cancer; molecular imaging; PET; radiopharmaceuticals

Indexed keywords

ARGININE GLYCINE ASPARTIC ACID; DIMETHYLAMINOMETHYLENEDIPHOSPHONATE TECHNETIUM TC 99M; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUORIDE F18; FLUORODEOXYGLUCOSE F 18; FLUOROTHYMIDINE F18; LIPOCORTIN 5; MARACICLATIDE; MARACICLATIDE TC 99M; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; TAMOXIFEN; TETROFOSMIN TC 99M; TRACER; UNCLASSIFIED DRUG;

APOPTOSIS; BONE SCINTISCANNING; BREAST CANCER; CANCER DIAGNOSIS; CANCER STAGING; CELL PROLIFERATION; ISOTOPE LABELING; MAMMOGRAPHY; MOLECULAR IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REVIEW; SCINTIMAMMOGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT RESPONSE;

BREAST NEOPLASMS; FEMALE; HUMANS; MOLECULAR IMAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84858394254     PISSN: 10849785     EISSN: 15578852     Source Type: Journal    
DOI: 10.1089/cbr.2011.1025     Document Type: Review

References (64)

1. American Cancer Society. Breast Cancer Facts & Figures 2009-2010, Vol. 2011, Atlanta, GA: American Cancer Society, 2010. Available online at www.cancer.org/acs/groups/content/@nho/document/f861009final90809pdf.pdf
2. Buerkle A, Weber WA. Imaging of tumor glucose utilization with positron emission tomography. Cancer Metastasis Rev 2008;27:545.
3. Jonson SD, Welch MJ. PET imaging of breast cancer with fluorine-18 radiolabeled estrogens and progestins. Q J Nucl Med 1998;42:8.
4. Buck AK, Schirrmeister H, Mattfeldt T, et al. Biological characterisation of breast cancer by means of PET. Eur J Nucl Med Mol Imaging 2004;31 Suppl 1:S80.
5. Lim HS, Yoon W, Chung TW, et al. FDG PET/CT for the detection and evaluation of breast diseases: usefulness and limitations. Radiographics 2007;27 Suppl 1:S197.
6. Schilling K, Narayanan D, Kalinyak JE, et al. Positron emission mammography in breast cancer presurgical planning: Comparisons with magnetic resonance imaging. Eur J Nucl Med Mol Imaging 2011;38:23.
7. Aukema TS, Rutgers EJ, Vogel WV, et al. The role of FDG PET/CT in patients with locoregional breast cancer recurrence: A comparison to conventional imaging techniques. Eur J Surg Oncol 2010;36:387.
8. Mahner S, Schirrmacher S, Brenner W, et al. Comparison between positron emission tomography using 2-fluorine-18fluoro-2-deoxy-D-glucose, conventional imaging and computed tomography for staging of breast cancer. Ann Oncol 2008;19:1249.
9. Schirrmeister H. Detection of bone metastases in breast cancer by positron emission tomography. Radiol Clin North Am 2007;45:669, vi.
10. Tseng J, Dunnwald LK, Schubert EK, et al. 18F-FDG kinetics in locally advanced breast cancer: Correlation with tumor blood flow and changes in response to neoadjuvant chemotherapy. J Nucl Med 2004;45:1829.
11. Filippi L, Pulcini A, Remediani S, et al. Usefulness of scin-timammography with tc-99m MIBI in clinical practice. Clin Nucl Med 2006;31:761.
12. Aktolun C, Bayhan H, Kir M. Clinical experience with Tc-99m MIBI imaging in patients with malignant tumors. Preliminary results and comparison with Tl-201. Clin Nucl Med 1992;17:171.
13. Scopinaro F, Schillaci O, Scarpini M, et al. Technetium-99m sestamibi: An indicator of breast cancer invasiveness. Eur J Nucl Med 1994;21:984.
14. Liberman M, Sampalis F, Mulder DS, et al. Breast cancer diagnosis by scintimammography: A meta-analysis and review of the literature. Breast Cancer Res Treat 2003;80:115.
15. Kim IJ, Bae YT, Kim SJ, et al. Determination and prediction of P-glycoprotein and multidrug-resistance-related protein expression in breast cancer with double-phase technetium-99m sestamibi scintimammography. Visual and quantitative analyses. Oncology 2006;70:403.
16. Cayre A, Cachin F, Maublant J, et al. Single static view 99mTc-sestamibi scintimammography predicts response to neoadjuvant chemotherapy and is related to MDR expression. Int J Oncol 2002;20:1049.
17. Hruska CB, Boughey JC, Phillips SW, et al. Scientific Impact Recognition Award: Molecular breast imaging: A review of the Mayo Clinic experience. Am J Surg 2008;196:470.
18. Ferrara A. Nuclear imaging in breast cancer. Radiol Technol 2010;81:233.
19. Oude Munnink TH, Nagengast WB, Brouwers AH, et al. Molecular imaging of breast cancer. Breast 2009;18 Suppl 3:S66.
20. Romer J, Fuchtner F, Steinbach J, et al. Automated synthesis of 16alpha-18Ffluoroestradiol-3,17beta-disulphamate. Appl Radiat Isot 2001;55:631.
21. Yoo J, Dence CS, Sharp TL, et al. Synthesis of an estrogen receptor beta-selective radioligand: 5-18Ffluoro-(2R,3S)-2,3-bis(4-hydroxyphenyl) pentanenitrile and comparison of in vivo distribution with 16alpha-18Ffluoro- 17beta-estradiol. J Med Chem 2005;48:6366.
22. Sundararajan L, Linden HM, Link JM, et al. 18F-fluor-oestradiol. Semin Nucl Med 2007;37:470.
23. Peterson LM, Mankoff DA, Lawton T, et al. Quantitative imaging of estrogen receptor expression in breast cancer with PET and 18F-fluoroestradiol. J Nucl Med 2008; 49:367.
24. Yang DJ, Li C, Kuang LR, et al. Imaging, biodistribution and therapy potential of halogenated tamoxifen analogues. Life Sci 1994;55:53.
25. Inoue T, Kim EE, Wallace S, et al. Positron emission tomography using 18Ffluorotamoxifen to evaluate therapeutic responses in patients with breast cancer: preliminary study. Cancer Biother Radiopharm 1996;11:235.
26. Moasser MM. The oncogene HER2: Its signaling and transforming functions and its role in human cancer pathogene-sis. Oncogene 2007;26:6469.
27. Capala J, Bouchelouche K. Molecular imaging of HER2-positive breast cancer: A step toward an individualized "image and treat" strategy. Curr Opin Oncol 2010;22:559.
28. Holland JP, Sheh Y, Lewis JS. Standardized methods for the production of high specific-activity zirconium-89. Nucl Med Biol 2009;36:729.
29. Dijkers EC, Oude Munnink TH, Kosterink JG, et al. Biodis-tribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther 2010;87:586.
30. Orlova A, Wallberg H, Stone-Elander S, et al. On the selection of a tracer for PET imaging of HER2-expressing tumors: Direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model. J Nucl Med 2009; 50:417.
31. Xu H, Baidoo K, Gunn AJ, et al. Design, synthesis, and characterization of a dual modality positron emission tomography and fluorescence imaging agent for monoclonal antibody tumor-targeted imaging. J Med Chem 2007; 50:4759.
32. Winberg KJ, Persson M, Malmstrom PU, et al. Radio-bromination of anti-HER2/neu/ErbB-2 monoclonal antibody using the p-isothiocyanatobenzene derivative of the 76Brundecahydro-bromo-7,8-dicarba-nido-un-decaborate(1-) ion. Nucl Med Biol 2004;31:425.
33. Sampath L, Kwon S, Ke S, et al. Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer. J Nucl Med 2007;48:1501.
34. Shields AF, Grierson JR, Dohmen BM, et al. Imaging proliferation in vivo with F-18FLT and positron emission tomography. Nat Med 1998;4:1334.
35. Reske SN, Deisenhofer S. Is 3-deoxy-3-(18)F-fluor-othymidine a better marker for tumour response than (18)F-fluorodeoxyglucose? Eur J Nucl Med Mol Imaging 2006;33 Suppl 1:38.
36. Seitz U, Wagner M, Neumaier B, et al. Evaluation of pyrimidine metabolising enzymes and in vitro uptake of 3-(18)Ffluoro-3-deoxythymidine ((18)FFLT) in pancreatic cancer cell lines. Eur J Nucl Med Mol Imaging 2002; 29:1174.
37. Munch-Petersen B, Cloos L, Jensen HK, et al. Human thy-midine kinase 1. Regulation in normal and malignant cells. Adv Enzyme Regul 1995;35:69.
38. Spence AM, Muzi M, Link JM, et al. NCI-sponsored trial for the evaluation of safety and preliminary efficacy of 3-deoxy-3-18Ffluorothymidine (FLT) as a marker of proliferation in patients with recurrent gliomas: Preliminary efficacy studies. Mol Imaging Biol 2009;11:343.
39. Pio BS, Park CK, Pietras R, et al. Usefulness of 3-F-18fluoro-3- deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. Mol Imaging Biol 2006;8:36.
40. Kenny L, Coombes RC, Vigushin DM, et al. Imaging early changes in proliferation at 1 week post chemotherapy: A pilot study in breast cancer patients with 3-deoxy-3-18Ffluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging 2007;34:1339.
41. Yun M, Oh SJ, Ha HJ, et al. High radiochemical yield synthesis of 3-deoxy-3-18Ffluorothymidine using (5-O-dimethoxytrityl-2-deoxy-3-O-nosyl-beta- D-threo pentofuranosyl)thymine and its 3-N-BOC-protected analogue as a labeling precursor. Nucl Med Biol 2003;30:151.
42. Machulla HJ, Blocher A, Kuntzsch M, et al. Simplified labeling approach for synthesizing 3-deoxy-3-F-18fluor-othymidine (F-18FLT). J Radioanal Nucl Chem 2000; 243:843.
43. Jager PL, Vaalburg W, Pruim J, et al. Radiolabeled amino acids: Basic aspects and clinical applications in oncology. J Nucl Med 2001;42:432.
44. Davis J, Yano Y, Cahoon J, et al. Preparation of 11C-methyl iodide and L-S-methyl-11Cmethionine by an automated continuous flow process. Int J Appl Radiat Isot 1982;33:363.
45. Lindholm P, Lapela M, Nagren K, et al. Preliminary study of carbon-11 methionine PET in the evaluation of early response to therapy in advanced breast cancer. Nucl Med Commun 2009;30:30.
46. Sharma R, Tripathi M, Panwar P, et al. 99mTc-methionine scintimammography in the evaluation of breast cancer. Nucl Med Commun 2009;30:338.
47. Takada Y, Ye X, Simon S. The integrins. Genome Biol 2007;8:215.
48. Ruoslahti E, Pierschbacher MD. New perspectives in cell adhesion: RGD and integrins. Science 1987;238:491.
49. Bach-Gansmo T, Danielsson R, Saracco A, et al. Integrin receptor imaging of breast cancer: A proof-of-concept study to evaluate 99mTc-NC100692. J Nucl Med 2006;47:1434.
50. Axelsson R, Bach-Gansmo T, Castell-Conesa J, et al. An open-label, multicenter, phase 2a study to assess the feasibility of imaging metastases in late-stage cancer patients with the alpha v beta 3-selective angiogenesis imaging agent 99mTc-NC100692. Acta Radiol 2010;51:40.
51. Haubner R, Wester HJ, Weber WA, et al. Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res 2001;61:1781.
52. Haubner R, Kuhnast B, Mang C, et al. 18FGalacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates. Bioconjug Chem 2004;15:61.
53. Beer AJ, Niemeyer M, Carlsen J, et al. Patterns of al-phavbeta3 expression in primary and metastatic human breast cancer as shown by 18F-Galacto-RGD PET. J Nucl Med 2008;49:255.
54. Gaertner FC, Schwaiger M, Beer AJ. Molecular imaging of avb3 expression in cancer patients. Q J Nucl Med Mol Imaging 2010 Jun; 54(3): 309-26 PMID:20639816.
55. Belhocine T, Steinmetz N, Li C, et al. The imaging of apo-ptosis with the radiolabeled annexin V: Optimal timing for clinical feasibility. Technol Cancer Res Treat 2004;3:23.
56. Kurihara H, Yang DJ, Cristofanilli M, et al. Imaging and dosimetry of 99mTc EC annexin V: Preliminary clinical study targeting apoptosis in breast tumors. Appl Radiat Isot 2008;66:1175.
57. Hamaoka T, Madewell JE, Podoloff DA, et al. Bone imaging in metastatic breast cancer. J Clin Oncol 2004;22:2942.
58. Kanishi D. 99mTc-MDP accumulation mechanisms in bone. Oral Surg Oral Med Oral Pathol 1993;75:239.
59. Yeh KA, Fortunato L, Ridge JA, et al. Routine bone scanning in patients with T1 and T2 breast cancer: A waste of money. Ann Surg Oncol 1995;2:319.
60. Mortimer JE, Dehdashti F, Siegel BA, et al. Metabolic flare: Indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol 2001;19:2797.
61. Han LJ, Au-Yong TK, Tong WC, et al. Comparison of bone single-photon emission tomography and planar imaging in the detection of vertebral metastases in patients with back pain. Eur J Nucl Med 1998;25:635.
62. Hawkins RA, Choi Y, Huang SC, et al. Evaluation of the skeletal kinetics of fluorine-18-fluoride ion with PET. J Nucl Med 1992;33:633.
63. Even-Sapir E, Metser U, Flusser G, et al. Assessment of malignant skeletal disease: Initial experience with 18F-fluoride PET/CT and comparison between 18F-fluoride PET and 18F-fluoride PET/CT. J Nucl Med 2004;45:272.
64. Schirrmeister H, Rentschler M, Kotzerke J, et al. Skeletal imaging with (FNa)-F-18-PET and comparison with planar skeletal scintigraphy. Rofo Fortschr Geb Rontgenstr Bildgeb Verfahr 1998;168:451.